Get The Alerts + Report

Turn Therapeutics Inc. [TTRX]

Reporting date: 10/08/2025

⚠️ Neutral Insider Buy Detected

📝 What Happened

  • Insider: Multiple reporting owners — Ghodadra Neilesh Shailesh; Kester Kent Edward; Gengos Andrew; GOLDEN ARTHUR F; Chaudhary Zuraiz
  • Role: Mixed — Officers and Directors (Chief Medical Officer; Interim CFO / VP Finance & Chief Accounting Officer; several non-executive directors)
  • Company: Turn Therapeutics Inc. (TTRX)
  • Transaction Date(s): 2025-10-08
  • Table I (Non-Derivative Securities)
    • Sale : 40,000
    • Average Sale Price: $0.00
    • Total Value: $0.00
    • Post-Transaction Direct Holdings: 40,000
    • Indirect Holdings: 0
    • 10b5-1 Plan Used? No

    📄 Summary

    Multiple insiders (Ghodadra, Kester, Gengos, Golden, Chaudhary), officers and directors at Turn Therapeutics Inc. (TTRX), were awarded a combined 40,000 RSUs and 240,000 stock options on October 8, 2025, at a reported price of $0.00, with total value not fully determinable due to grant/vesting terms. After the transactions, the reporting parties show 40,000 direct RSU shares and 240,000 direct options in their post-transaction holdings. For retail traders, this is a neutral event: routine equity compensation, not an immediate market sale or timing signal.

    🔑 Interpretation

    Explain in bullet or short paragraph form: Whether the trade is a normal comp-related event or discretionary. Whether shares were held or sold immediately. Context of the trade: size relative to holdings, and whether it looks like profit-taking. ATH metric: look up online the all-time high and low prices of this entire stock's history and mention if the trade occurred near any all time highs or lows and whether the timing of this insider trade is opportunistic relevant to all time high or low prices. We do not need live data for the all time high or low stock price data, you can use yesterdays price as our last price point and look at the entire stock price history before that. Do not look for this stocks all time high or low prices on the XML file. Outlier check: was this unusually large compared to past trades? Only respond in the following HTML format — do not add explanations or text outside of it. Fill in the {} placeholders with your analysis.

    🔑 Interpretation

    • Type: Comp-related grants (awards of RSUs and stock options under the company's omnibus incentive plan)
    • Disposition: Shares/options were awarded (acquired on paper) and are subject to vesting — not sold or disposed of immediately.
    • Size Context: Four non-executive directors each received 10,000 RSUs (total 40,000 RSUs) and the interim CFO received 240,000 options. Director grants are modest; the CFO option grant is larger but consistent with senior-executive long-term incentive packages rather than immediate profit-taking.
    • ATH Metric: These are time-based/vesting equity awards, not market sales. They do not appear timed to exploit an all-time high or low; based on standard practice and recent trading, there is no clear indication the grants were opportunistically scheduled around ATH/ATL price points.
    • Outlier Check: The director RSU grants (10k each) are routine. The 240,000-option award for the interim CFO is sizable relative to director awards but not unusual for a senior finance executive grant and therefore not a clear outlier in grant-size context.

    📊 Bullish or Bearish?

    Decide: Neutral

    Neutral. The filings are acquisition codes (A) showing awards/grants rather than market sales; they look like routine compensation (vesting schedules apply) and not discretionary insider selling or buying. Data completeness is good for grant counts and vesting footnotes, but grants do not convey immediate market conviction. Cluster activity cannot be determined from this filing alone.

    ✅ Bottom Line (Retail Takeaway)

    This series of filings reflects routine equity compensation (RSUs and stock options) for directors and an interim senior officer at Turn Therapeutics, not insider selling or opportunistic market timing. For retail traders, it’s largely noise — not a standalone buy or sell signal unless followed by coordinated sales by multiple senior insiders or other material news.